Clinical resource
Oesophageal neoadjuvant EBRT chemoradiation (eviQ ID 1861)
eviQ, Cancer Institute NSW
DoseLab summary
Endorsed eviQ protocol for preoperative chemoradiation of esophageal and gastroesophageal junction cancer: 41.4 Gy in 23 fractions with weekly carboplatin and paclitaxel, the CROSS regimen. It recommends PET/CT to aid tumor delineation and 4DCT especially for gastroesophageal junction tumors, and its lung limits are deliberately more conservative than in the definitive protocol to lower the risk of pulmonary complications after surgery.
Why this is useful
The CROSS-style preoperative schedule with an organ table for the lungs, heart, liver, kidneys, spleen and cord — including tighter lung limits for patients going on to surgery.
Reference details
- Title
- Oesophageal neoadjuvant EBRT chemoradiation (eviQ ID 1861)
- Authors / organization
- eviQ, Cancer Institute NSW
- Publication / protocol
- eviQ Radiation Oncology protocol 1861
- Version
- v.8 — last reviewed 17 October 2025; review due 31 December 2027
- Year
- 2025
- DOI
- Pending verification
- Disease sites
- GI
- Topics
- Esophagus, Preoperative, Conventional fractionation, Dose Constraints, Protocols
- Fractionation context
- 41.4 Gy / 23 fx
- Last reviewed by DoseLab
- 2026-09-29